In recent years,with the development of disease-modifying therapies(DMT)such as monoclonal antibodies against amyloid-beta protein(Aβ),drug treatment for Alzheimer's disease(AD)has entered a new era.Currently,two antibodies targeting Aβ—aducanumab and lecanemab—have been approved for clinical use,attracting widespread attention worldwide.Meanwhile,remark-able progress has also been made in the development of drugs against non-Aβ and non-tau targets.This review highlights the latest ad-vances in the development and application of drugs for AD that have been clinically approved or in clinical trials.
关键词
阿尔茨海默病/药物治疗/Aβ单克隆抗体/sigma受体相关药物
Key words
Alzheimer's disease/pharmacotherapy/anti-amyloid-beta monoclonal antibody/sigma receptor-targeting drug
维普
万方数据